eClinical Tech News

Medicenna will unveil updated ABILITY-1 Phase 1/2 data for its long-acting IL-2 superkine MDNA11—both as monotherapy and in combination...

Praxis secured FDA agreement to convert EMBRAVE3, its registrational study of elsunersen in early-onset SCN2A developmental and epileptic encephalopathy,...

Amneal secured FDA approval for epinephrine injection USP, 1 mg/mL, in 1 mL single-dose and 30 mL multi-dose vials...

RAP-219 cut median clinical seizure frequency by 77.8% over eight weeks in a 30-patient Phase 2a study of drug‑resistant...

Topline data: In triple-class–exposed multiple myeloma patients with three prior lines of therapy from CARTITUDE-1, a single infusion of...

Preclinical data presented at ASH showed that Prelude Therapeutics’ JAK2V617F-selective JH2 inhibitor PRT12396 inhibited mutant JAK2 signaling while preserving...

In a Phase Ib/II study of 103 patients with myeloid malignancies, lisaftoclax plus azacitidine delivered an overall response rate...

Objective response rate of 83% with two complete responses and a median progression-free survival of 22.1 months were reported...

In a humanized high-grade B‑cell lymphoma xenograft model, ARV‑393 combined with glofitamab delivered 81% tumor growth inhibition with concomitant...

In updated Phase 1/2 data from 31 sickle cell disease patients treated with ristoglogene autogetemcel (risto-cel; formerly BEAM-101), mean...